中药对重症肌无力患者疗后复发及肌无力危象影响的Meta分析

详细信息    查看全文 | 推荐本文 |

英文篇名：Chinese Medicine for Influencing Relapse and Myasthenia Gravis Crisis of Patients with Myasthenia Gravis: a Meta-analysis of Randomized Control Trials 作者：孙红艳 ; 吕安坤 英文作者：Sun Hongyan;Lv Ankun;School of Public Health, Xinjiang Medical University;EMG Room, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University; 关键词：中药 ; 重症肌无力 ; 复发 ; 重症肌无力危象 ; Meta分析 英文关键词：Chinese medicine;;myasthenia gravis;;relapse;;myasthenia gravis crisis;;Meta-analysis 中文刊名：SJKX 英文刊名：Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology 机构：新疆医科大学公共卫生学院;新疆医科大学附属中医医院肌电图室; 出版日期：2019-04-20 出版单位：世界科学技术-中医药现代化 年：2019 期：v.21 基金：新疆维吾尔自治区自然科学基金(2014211C021):新疆原发性干燥综合征气阴两虚证与miRNA-146a相关性研究,负责人:孙红艳;; 新疆医科大学科研创新基金(XYDCX201406):原发性干燥综合征患者血miRNA-146a水平与气阴两虚证的相关性分析,负责人:孙红艳 语种：中文; 页：SJKX201904008 页数：7 CN：04 ISSN：11-5699/R 分类号：66-72

摘要

目的:评价中药对重症肌无力疗后复发及重症肌无力危象发生率的影响效果。方法:检索相关数据库,查找中药治疗重症肌无力的随机对照试验文献,对采集的数据进行系统评价。结果:共纳入13篇文献,包括1 137例患者。纳入文献质量均为低质量文献。研究显示:与西药组疗后复发率相比,中成药组有统计学意义(P <0.000 01),"中成药+西药"组有统计学意义(P <0.000 01),"中药复方+西药"组有统计学意义(P=0.000 03);与西药组疗后肌无力危象发生率相比,"中成药+西药"组有统计学意义(P <0.000 1),"中药复方+西药"组有统计学意义(P=0.02)。结论:现有证据表明,中成药治疗重症肌无力后的复发率低;在西药基础上联用中成药或中药复方可以降低重症肌无力治疗后的复发率和肌无力危象发生率。但上述结论仍需大样本试验加以验证。
        The aim of the study was to assess the effect of Chinese medicine in the treatment of myasthenia gravis on the incidence of recurrence and myasthenia gravis crisis. This study completely searched for Chinese medicine treatment of myasthenia gravis, which were randomized controlled trials from some Databases. The information was recorded and analyzed. A total of 13 randomized controlled trials involving 1137 patients were included. All included literatures were low-quality. Meta-analysis showed that, compared with the recurrence rate after treatment of myasthenia gravis in the western medicine group, there was statistical significance in the results of the Chinese patent medicine group(P < 0.00001), the western medicine plus Chinese patent medicine group(P < 0.000 01) and the western medicine plus Chinese medicine compound group(P = 0.000 03). Compared with the incidence of myasthenia gravis crisis in the western medicine group, there was statistical significance in the results of the western medicine plus Chinese patent medicine group(P < 0.00 01) and the western medicine plus Chinese medicine compound group(P = 0.02). The current evidence confirmed that, the recurrence rate of Chinese patent medicine for myasthenia gravis was low; Chinese patent medicine or Chinese medicine compound based on the use of western medicine can reduce the recurrence rate of myasthenia gravis and the incidence of myasthenia gravis crisis. However, the above conclusion still needs clinical trials with large sample to be verified.

引文

1陈乐君,顼宝玉,王娟,等.重症肌无力中西医结合治疗研究进展.中西医结合心脑血管病杂志,2017,15(22):2840-2841.
    2傅芳.中医药治疗重症肌无力Meta分析.亚太传统医药,2015,11(20):42-44.
    3 Yang X Q,Liu L,Yang W Y,et al.Efficacy and safety of the TCM qisupplementing therapy in patients with myasthenia gravis:a systematic review and Meta-analysis.Evid Based Complement Alternat Med.2017:6512572.
    4吕安坤,孙红艳.中药治疗重症肌无力随机对照试验的Meta分析.世界科学技术-中医药现代化,2015,17(7):1492-1503.
    5 Jadad A R,Moore R A,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary.Control Clin Trials,1996,17(1):1-12.
    6 Conti-Fine B M,Milani M,Kaminski H J.Myasthenia gravis:past,present,and future.J Clin Invest,2006,116(11):2843-2854.
    7陈德庆.68例重症肌无力危象的临床分析.中国实用医药,2013,8(34):38.
    8李红梅.重症肌无力危象诱因及临床治疗分析.中国保健营养,2016,26(9):34.
    9王昆祥,孟淑红,张春野,等.重症肌无力伴呼吸衰竭的临床分析.医学信息,2015,28(48):62.
    10 Sieb J P.Myasthenia gravis:an update for the clinician.Clin Exp Immunol,2014,175(3):408-418.
    11陈群,鲁卫华,秦雪梅,等.胸腺切除术后并发重症肌无力危象的救治经验总结.中国全科医学,2016,19(23):2833.
    12蔡小军,朱雯华,刘珏,等.单克隆抗体在重症肌无力治疗中的应用进展.中华神经医学杂志,2018,17(8):851-855.
    13詹青,曹惠芬,林丽,等.重症肌无力西医分型与中医辨证论治的相关性研究.中国现代医学杂志,2007,17(4):472-474.
    14刘少云.尚尔寿教授诊治重症肌无力经验摭拾.中华中医药学刊,2001,19(4):306.
    15吴相春,来静.吴以岭诊治重症肌无力的学术思想及经验.江苏中医药,2009,41(3):25-26.
    16洪霞,郭春莉,宁侠,等.周绍华治疗重症肌无力经验.中医杂志,2016,57(13):1093-1095.
    17王宏涛,殷世平.强肌合剂治疗ⅡA型重症肌无力80例.中国药业,2010,19(12):75-76.
    18肖勇洪,秦天楠,王鑫浩,等.彭江云辨治重症肌无力经验浅探.内蒙古中医药,2017(13):57.
    19杨曈,林丽.重症肌无力的中西医治疗进展.神经病学与神经康复学杂志,2018,14(2):111-116.
    20孙玉芹.中西医结合治疗重症肌无力的临床观察.中国卫生产业,2014,10(17):180-181.
    21黄运强.中西医结合抢救38例重症肌无力危象临床分析.中国医药科学,2014,4(4):195-196.
    22姜超,刘萍,梁燕.重症肌无力中西医结合治疗思路探讨.中国中医急症,2012,21(3):365-367.
    23董秀娟,刘小斌,邱向红.重症肌无力危象诱因防治与临床相应措施.新中医,2012,44(6):189-191.
    24徐鹏,吕志国,张影,等.基于循证医学的重症肌无力中医文献质量评价研究报告.世界中医药,2017,12(1):191-194.